JPM
Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
Antengene; JPM Conference; ATG-022; ADCs; TCEs; AnTenGager; ATG-125; ATG-207
Eli Lilly and Nvidia Announce $1 Billion, Five-Year AI Co-Innovation Lab Partnership in Bay Area
Eli Lilly; Nvidia; AI lab; drug discovery; $1 billion; Bay Area; JPM 2026
Navigating JPM 2026: Biotech/Biopharma Trends, Policy Impacts, and Forward Outlook
JPM 2026; biotech trends; biopharma trends; healthcare policy; AI in drug discovery; financing strategy; dealmaking; innovation
Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings
Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market
GSK Initiates JPM Deal-making with $1 Billion Acquisition of IDRx for Rare Cancer Treatment
GSK, IDRx, JPM, rare cancer, acquisition, biotech, pharmaceuticals
Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025
JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology
Navigating JPM Week 2024: Insights and Opportunities in Biopharma
JPM Week 2024, Biopharma, Industry Insights, Networking, Deal-making, Investment, M&A, IPOs, Regulatory Trends